TNGXTango Therapeutics, Inc.Running, no new patients
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Non Small Cell Lung Cancer · Solid Tumors, Adult · Lung Cancer · Lung Adenocarcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 126 (planned)
- Started
- Jun 12, 2023
- Main results expected
- Sep 2026
- Fully finished
- Sep 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Determine the MTD and RP2D(s) (Phase 1 only)
Measured over: 42 days
Measure antitumor activity using RECIST 1.1 (Phase 2 only)
Measured over: 12 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05887492 · record last updated 2026-07-06 · checked 2026-11-09 15:47 UTC